{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000999","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.982407+00:00","generated_at":"2026-06-24T04:51:10.785204+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Charles River Q2 revenue $973.1M (+6.4% YoY); non-GAAP EPS $2.77 (+6.1%); cuts FY22 guidance","bullets":["GAAP EPS $2.13 vs $1.72 Q2 2021; non-GAAP EPS $2.77 vs $2.61.","Revenue $973.1M, organic growth 9.5% led by DSA and RMS segments.","FY22 guidance cut: organic rev growth 10-12% (prev 12.5-14.5%), non-GAAP EPS $10.70-$10.95 (prev $11.50-$11.75).","DSA segment revenue $591.9M (+12.9% organic); operating margin improved to 25.3% non-GAAP.","Manufacturing segment revenue $194.8M (-1.5%); CDMO weakness offset by Biologics Testing growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000999","json":"https://secwatch.observer/filing/0001157523-22-000999.json","markdown":"https://secwatch.observer/filing/0001157523-22-000999.md","text":"https://secwatch.observer/filing/0001157523-22-000999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752322000999/0001157523-22-000999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752322000999/a52799763.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:51:10.785204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}